Emixef 200 Capsule: Each capsule contains Cefixime Trihydrate USP equivalent to Cefixime 200 mg.
Emixef 400 Capsule: Each capsule contains Cefixime Trihydrate USP equivalent to Cefixime 400 mg.
Emixef Powder for Suspension: After reconstitution according to direction, each 5 ml suspension contains Cefixime Trihydrate USP equivalent to Cefixime 100 mg.
Emixef DS Powder for Suspension: After reconstitution according to direction, each 5 ml suspension contains Cefixime Trihydrate USP equivalent to Cefixime 200 mg.
Cefixime is a semi-synthetic, broad spectrum cephalosporin antibiotic of third generation for oral administration. It is a bactericidal antibiotic, kills bacteria by interfering in the synthesis of the bacterial cell wall. Cefixime is highly stable in the presence of beta-lactamase enzymes. Cefixime has marked in-vitro bactericidal activity against a wide variety of Gram-positive and Gram-negative organisms including beta lactamase producers.
Clinical efficacy of Cefixime has been demonstrated in infections caused by commonly occurring pathogens including Gram-positive organism Streptococcus pneumoniae, Streptococcus pyogenes, Gram-negative organism Escherichia coli, Proteus mirabilis, Klebsiella spp., Haemophilus influenzae (beta-lactamase positive and negative), Moraxella catarrhalis (beta-lactamase positive and negative), Salmonella typhi and Enterobacter species.
Emixef is indicated in the following infectious diseases -
Respiratory Tract Infections:
• Pharyngitis and Tonsillitis
• Acute Bronchitis and Acute Exacerbations of Chronic Bronchitis (AECB)
Urinary Tract Infections
Uncomplicated gonorrhea (cervical/urethral).
Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses
Child over 6 months: 8mg/kg daily as a single or in 2 divided doses
The usual treatment of Emixef is 7 days. This may be continued for up to 14 days according to the severity of infection.
|Patient Weight (Kg)||Dose (mg/day)||Emixef Dose (ml/day)||Emixef DS Dose (ml/day)|
Cefixime is generally well tolerated. The majority of adverse reactions observed in clinical trials are mild and self limiting in nature.
Gastro-intestinal disturbance: Diarrhea (if severe diarrhea occurs, Cefixime should be discontinued), changes in the color of stool, nausea, abdominal pain, dyspepsia, vomiting, flatulence have been reported.
CNS disturbances: Headache, dizziness.
Others: Hypersensitivity reactions which usually subsided upon discontinuation of therapy; infrequent and reversible hematological changes; elevation of serum amylase.
Cefixime should be prescribed with caution in individuals with a history of gastrointestinal diseases, particularly colitis. Dosage adjustment is only necessary in severe renal failure (creatinine clearance < 20 ml/min)
Pregnancy: Pregnancy category B. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Lactation: It is not known whether Cefixime is excreted in human milk. Consideration should be given to discontinuing nursing temporarily during treatment with this drug.